89bio, Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
ETNB Company Description
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
ETNB Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view ETNB Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of ETNB by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ETNB's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of ETNB in WallStreetBets Daily Discussion
ETNB News
Recent insights relating to ETNB
CNBC Recommendations
Recent picks made for ETNB stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in ETNB
Corporate Flights
Flights by private jets registered to ETNB
Our Analysis